Your browser doesn't support javascript.
loading
FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.
Kiiski, Johanna I; Tervasmäki, Anna; Pelttari, Liisa M; Khan, Sofia; Mantere, Tuomo; Pylkäs, Katri; Mannermaa, Arto; Tengström, Maria; Kvist, Anders; Borg, Åke; Kosma, Veli-Matti; Kallioniemi, Anne; Schleutker, Johanna; Bützow, Ralf; Blomqvist, Carl; Aittomäki, Kristiina; Winqvist, Robert; Nevanlinna, Heli.
Afiliación
  • Kiiski JI; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Tervasmäki A; Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Pelttari LM; Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre, NordLab, Oulu, Finland.
  • Khan S; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Mantere T; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Pylkäs K; Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Mannermaa A; Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre, NordLab, Oulu, Finland.
  • Tengström M; Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Kvist A; Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre, NordLab, Oulu, Finland.
  • Borg Å; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, and Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland.
  • Kosma VM; Imaging Center, Clinical Pathology, Kuopio University Hospital, Kuopio, Finland.
  • Kallioniemi A; School of Medicine, Institute of Clinical Medicine, Oncology, Kuopio, Finland.
  • Schleutker J; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
  • Bützow R; Division of Oncology and Pathology Department of Clinical Sciences Lund, Lund University, Medicon Village, Lund, Sweden.
  • Blomqvist C; Division of Oncology and Pathology Department of Clinical Sciences Lund, Lund University, Medicon Village, Lund, Sweden.
  • Aittomäki K; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, and Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland.
  • Winqvist R; Imaging Center, Clinical Pathology, Kuopio University Hospital, Kuopio, Finland.
  • Nevanlinna H; BioMediTech Institute and Faculty of Medicine and Life Sciences, University of Tampere, and Fimlab Laboratories, Tampere, Finland.
Breast Cancer Res Treat ; 166(1): 217-226, 2017 Nov.
Article en En | MEDLINE | ID: mdl-28702895
ABSTRACT

PURPOSE:

The FANCM c.5101C>T nonsense mutation was previously found to associate with breast cancer in the Finnish population, especially among triple-negative cases. Here, we studied the prevalence of three other FANCM variants c.5791C>T, which has been reported to predispose to familial breast cancer, and the c.4025_4026delCT and c.5293dupA variants recently identified in Finnish cancer patients.

METHODS:

We genotyped the FANCM c.5791C>T mutation in 4806 invasive breast cancer patients, including BRCA1/2 mutation negative familial cases and unselected cases, and in 2734 healthy population controls from four different geographical areas of Finland. The association of the mutation with breast cancer risk among patient subgroups was statistically evaluated. We further analyzed the combined risk associated with c.5101C>T and c.5791C>T mutations. We also genotyped 526 unselected ovarian cancer patients for the c.5791C>T mutation and 862 familial breast cancer patients for the c.4025_4026delCT and c.5293dupA variants.

RESULTS:

The frequency of the FANCM c.5791C>T mutation was higher among breast cancer cases than in controls (OR 1.94, 95% CI 0.87-4.32, P = 0.11), with a statistically significant association with triple-negative breast cancer (OR 5.14, 95% CI 1.65-16.0, P = 0.005). The combined analysis for c.5101C>T and c.5791C>T carriers confirmed a strong association with breast cancer (OR 1.86, 95% CI 1.32-2.49, P = 0.0002), especially among the triple-negative patients (OR 3.08, 95% CI 1.77-5.35, P = 0.00007). For the other variants, only one additional c.4025_4026delCT carrier and no c.5293dupA carriers were observed.

CONCLUSIONS:

These results support the role of FANCM as a breast cancer susceptibility gene, particularly for triple-negative breast cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: ADN Helicasas / Predisposición Genética a la Enfermedad / Alelos / Neoplasias de la Mama Triple Negativas / Mutación Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans País/Región como asunto: Europa Idioma: En Revista: Breast Cancer Res Treat Año: 2017 Tipo del documento: Article País de afiliación: Finlandia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: ADN Helicasas / Predisposición Genética a la Enfermedad / Alelos / Neoplasias de la Mama Triple Negativas / Mutación Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans País/Región como asunto: Europa Idioma: En Revista: Breast Cancer Res Treat Año: 2017 Tipo del documento: Article País de afiliación: Finlandia